Liver Cancer Drug Market Size To Reach $7.83 Billion By 2030

Liver Cancer Drug Market Growth & Trends

The global liver cancer drug market size is expected to reach USD 7.83 billion by 2030, registering a CAGR of 15.3% during the forecast period, according to a new report by Grand View Research, Inc. The growth of liver cancer market is largely driven by factors such as availability of novel drugs, presence of strong pipeline, and rising public awareness. Widening base of liver cancer patients can be attributed to unhealthy lifestyles and growing geriatric population. This, in turn, is working in favor of the liver cancer therapeutics market. Therapeutic development in second-line setting for Nexavar-intolerant patients is estimated to have a major impact in the HCC space.

Liver cancer is the fifth most prevalent cancer worldwide and accounts for 9.0% of all cancer deaths. In 2012, 782,451 new cases of liver cancer were diagnosed, and 745,533 deaths were reported due to liver cancer. Primary liver cancer remains an important public health issue due to its extremely aggressive nature and poor survival rate. Hepatocellular carcinomas (HCCs) represents the majority (75–90%) of primary liver cancers. A noteworthy number of etiological factors of liver cancer, including hepatitis infection and cirrhosis, can be modified and present a strong prospect to reduce its incidence and mortality by preventive strategies such as lifestyle modification and hepatitis immunization.

 Request a free sample copy or view report summary: Liver Cancer Drug Market Report

Liver Cancer Drug Market Report Highlights

• The North America accounted for more than 43.20% of the market in 2022. Multiple product launches, increasing adoption of novel therapeutics, and presence of a large target population are contributing to the growth of the market in the region

• Approval of multiple novel drugs in recent years is one of the key factors augmenting the liver cancer treatment market. New immuno-oncology products and combination therapies are anticipated to change the landscape over the next years.

• Combination regimens, specifically those including checkpoint inhibitors, will be introduced in the first-line setting to target major unmet needs, including overcoming tumour resistance, improving progression free survival, and maintaining quality of life

• The liver cancer market pipeline is highly innovative and diverse. The market offers tremendous opportunities to develop breakthrough first-in-class therapies due to high unmet needs. In recent years, innovative treatment approaches such as oncolytic viruses or RNA interference (RNAi) technology have gained significant traction in the market.

Liver Cancer Drug Market Segmentation

Grand View Research has segmented the global liver cancer drug market on the basis of drug class, and region:

Liver Cancer Drug Drug Class Outlook (Revenue, USD Million, 2018 - 2030)

• Targeted Therapy

• Immunotherapy

• Chemotherapy

Liver Cancer Drug Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • Thailand

  • South Korea

• Latin America

  • Brazil

  • Mexico

  • Argentina

• Middle East and Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Liver Cancer Drug Market

• Bayer AG

• Bristol-Myers Squibb Company

• Eisai Co., Ltd.

• Exelixis, Inc.

• Merck KGaA